Search NLS News

These five Nordic life science companies are at different stages of development, with different focus areas, from different Nordic countries, and they represent the different strongholds that the region possesses.     Sweden – Abera Bioscience Abera Bioscience has found the right recipe for giving its versatile vaccine platform the best possible conditions to succeed. “Our […]

The company’s study is published in the journal Obesity, and also chosen as “Editor’s Choice” for the November issue. The aim of Empros Pharma’s study was to evaluate the effect of a novel, oral, modified-release formulation of the lipase inhibitor orlistat and the glucosidase/amylase inhibitor acarbose (denoted EMP16) on relative body weight after 26 weeks compared […]

The Finnish company has signed a second clinical trial collaboration and supply agreement with MSD for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with Keytruda, MSD’s anti-PD-1 therapy. This Phase I, open label, dose escalation trial will include 12 to 24 patients with immune checkpoint inhibitor […]

Oncopeptides has announced that the Oncologic Drugs Advisory Committee (ODAC), of the FDA, has finalized the discussion on the benefit-risk profile of Pepaxto. A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population. “We still have confidence in our science and data. The heart […]

AstraZeneca and MSD’s Lynparza has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. The PAOLA-1 Phase […]

During a meeting at the US ambassador’s residence in Sweden on September 20th, collaboration on data driven life sciences and Real World Evidence’s (RWE’s) impact on Swedish life sciences was discussed. The meeting was arranged by MSD, SwedenBIO, Karolinska Institutet and the American Chamber of Commerce. “The event was important in order to showcase concrete […]

Evusheld, a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. “COVID-19 remains an ongoing health concern for millions of Europeans and around the world, especially for […]

Cyxone has received approvals from the Medical Product Agency and the Central Ethics Committee in Poland to start a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). “The approval is a very important milestone for us. Cyxone have now finally the possibility to […]

Alligator Bioscience and Aptevo Therapeutics have announced the “may proceed” notification for the ALG.APV-527 investigational new drug application (IND). The notification allows the companies to initiate clinical trials evaluating the compound for the treatment of 5T4-expressing tumor antigens in multiple solid tumor types. They are moving rapidly to initiate a multi-center Phase 1 trial in […]

The Board of NorthX Biologics has appointed the former Director General of SwedenBIO, Helena Strigård, as their new Chief Executive Officer. She will lead NorthX’s continued expansion in the development and production of advanced biologics. Ted Fjällman, current CEO of NorthX and Partner of the company’s main investor, Flerie Invest, will continue to support the […]